Diabetogia: The effect of ertugliflozin on kidney function at 104 weeks of treatment?

The purpose of !---- the study was to assess the effects of the sodium glucose co-transporter 2 (SGLT2) inhibitor ertugliflozin on eGFR and albuminuria (uribrine/myonin ratio (UACR) in a 104-month treatment compared to gremetria or eergligliozinUsing two randomized controlled data from the ertflouglizin Effectiveness and Safety (VERTIS) (Clinicaltrials.gov NCT01999218 (VERTIS SU) and NCT02033889 (VERTIS MET) evaluation, the summary data of the active comparison study were used(VERTIS MET)) evaluated two randomized controlled, actively compared the summary data of the studyIn the VERTIS SU study, ertugliflozin and Gremeyin were evaluated over a 104-week periodIn the VERTIS MET study, ertugliflozin was evaluated over a 26-week period compared to a placebo; from week 26 to 104, eligible participants were changed from placebo to blind gremeThe blood sugar effects of eruglitflozin and non-ertugliflozin were also evaluated in the combined populationFinally, the researchers explored the average changes in eGFR and UACR over a 104-week periodOverall, the average of the baseline eGFR (SD) is 88.2 (18.8) ml min-1 (1.73 m) -2, and the geometric average of the baseline UACR (95% CI) is 1.31 mg/mmol (1.23, 1.38)In week 6, ertugliflozin 5 mg, ertugliflozin 15 mg and non-ertugliflozin group eGFR compared to the baseline of 2.3, -2.7 and -0.7 ml min-1 (1.73 m)-2, respectivelySince then, the average eGFR of the ertflouglizin group has increased over time, rather than the eGFR decreases in the ertugliflozin groupIn week 104, the changes in the eGFR of the eruglitflozin group of 5 mg, ertugliflozin 15 mg and non-ertugliflozin group eGFR were - 0.2, 0.1 and - 2.0 ml min - 1 (1.73 m) - 2In 415 patients with proteinuria at baseline (21.4 percent of the queue), the ertugliflozin group decreased even more in all measurement times and uACR at week 104Week 104, the UACR difference (95% CI) not corrected by ertugliflozin is - 29.5% (- 44.8, - 9.8; pAt 104 weeks, the treatment group changed similar to the baseline minimum-squares average of HbA1c (mmol/mol (95% CI): ertugliflozin 5 mg, ertugliflozin 15 mg and non-ertflozzi The in groups were - 6.84 (-7.64, -6.03), - 7.74 (-8.54, -6.94) and - 6.84 (-7.65, -6.03)In week 104, the minimum two-squares average (% (95% CI)) of the eruglitflozin 5 mg, ertugliflozin 15 mg and non-ertugliflozin group HbA1c compared to the baseline were:- 0.63 (-0.70, -0.55), - 0.71 (-0.78, -0.64) and -0.63 (-0.70, -0.55)Ertflouglizin reduced eGFR in week 6, consistent with the pharmacoactive effects of known SGLT2 inhibitors on kidney functionAfter 104 weeks, the eGFR value returned to the baseline level and the eGFR value of ertugliflozin therapy was higher than that of non-ertugliflozin therapy, although there was no difference in the change between the two groups in HbA1cThe results showed that Ertflouglizin reduced UACR in patients with baseline proteinuria